Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
Eli Lilly and Company
J Randolph Hecht; Sara Lonardi; Johanna Bendell; Hao-Wen Sim; Teresa Macarulla; Charles D Lopez; Eric Van Cutsem; Andres J Muñoz Martin; Joon Oh Park; Richard Greil; Hong Wang; Rebecca R Hozak; Ivelina Gueorguieva; Yong Lin; Sujata Rao; Baek-Yeol Ryoo